Gilead Sciences (GILD) Gross Margin (2009 - 2026)
Gilead Sciences' (GILD) quarterly Gross Margin came in at 79.76% in Q2 2026, up 96.0% on a YoY basis from 40.7% in Q2 2025, and up 0.66% quarter-over-quarter from 79.24% in Q1 2026.
Powered by 
Analysis
Gilead Sciences (GILD) Gross Margin (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has reported Gross Margin for 18 consecutive years, with 79.76% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Gross Margin rose 96.0% year-over-year to 79.76%; the trailing twelve-month figure through Jun 2026 stood at 79.59% (up 105.0% YoY), and the FY2025 full-year result was 78.83%, up 57.0% from the prior year.
- Gross Margin rose to 79.76% in Q2 2026 per GILD's latest filing, from 79.24% in the prior quarter.
- Across five years, Gross Margin topped out at 81.11% in Q4 2022 and bottomed at 70.62% in Q4 2023.
- Historically, Gross Margin has averaged 78.22% across 5 years, with a median of 78.6% in 2025.
- The sharpest annual moves came in 2022 and 2023: Gross Margin surged 1737 bps in 2022, then sank 1049 bps in 2023.
- Over 5 years, Gross Margin stood at 81.11% in 2022, then slipped by 13 bps to 70.62% in 2023, then gained by 12 bps to 79.11% in 2024, then rose by 1 bps to 79.51% in 2025, then gained by 0 bps to 79.76% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 79.76%, 79.24%, and 79.51% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.11 Bn | 193.12 Bn | 7.24 Bn | 72.04% |
| 2 | Gilead Sciences | 178.91 Bn | 175.73 Bn | 6.22 Bn | 79.76% |
| 3 | Vertex Pharmaceuticals | 131.35 Bn | 123.50 Bn | 2.84 Bn | 85.33% |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.85 Bn | 3.93 Bn | 91.59% |
| 5 | Argenx Se | 61.06 Bn | 55.87 Bn | 1.37 Bn | 90.43% |
| 6 | Moderna | 53.08 Bn | 47.94 Bn | 52.00 Mn | 35.86% |
| 7 | Alnylam Pharmaceuticals | 33.32 Bn | 30.01 Bn | 992.69 Mn | 76.90% |
| 8 | Biogen | 31.70 Bn | 30.41 Bn | 1.96 Bn | 71.60% |
| 9 | Roivant Sciences | 29.48 Bn | 29.48 Bn | 1.16 Mn | 80.31% |
| 10 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 84.20% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 79.76% |
| Mar 31, 2026 | 79.24% |
| Dec 31, 2025 | 79.51% |
| Sep 30, 2025 | 79.80% |
| Jun 30, 2025 | 78.81% |
| Mar 31, 2025 | 76.90% |
| Dec 31, 2024 | 79.11% |
| Sep 30, 2024 | 79.14% |
| Jun 30, 2024 | 77.80% |
| Mar 31, 2024 | 76.79% |
| Dec 31, 2023 | 70.62% |
| Sep 30, 2023 | 77.80% |
| Jun 30, 2023 | 78.15% |
| Mar 31, 2023 | 77.94% |
| Dec 31, 2022 | 81.11% |
| Sep 30, 2022 | 80.19% |
| Jun 30, 2022 | 76.96% |
| Mar 31, 2022 | 78.39% |
| Dec 31, 2021 | 63.74% |
| Sep 30, 2021 | 83.52% |